EUCTR2012-000769-19-NL进行中（未招募）不适用
Randomized phase II study of BEZ235 or everolimus in advanced pancreatic neuroendocrine tumors
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Advanced histologically confirmed well differentiated pancreatic neuroendocrine tumor - Progressive disease within the last 12 months - Measurable disease per RECIST Version 1.0 determined by multiphase MRI or triphasic CT Other protocol-defined inclusion criteria may apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •Exclusion Criteria: - Prior treatment with mTOR or PI3K inhibitors -Patients with more than 2 prior systemic treatment regimens - Previous cytotoxic chemotherapy, targeted therapy, or biotherapy within the last 4 weeks Other protocol-defined inclusion/exclusion criteria may apply
研究者
相似试验
进行中（未招募）
不适用
Safety and efficacy of BEZ235 in patients with pancreatic neuroendocrine tumors (pNET)Adult patient in advanced pancreatic neuroendocrine tumorsMedDRA version: 15.0Level: LLTClassification code 10068916Term: Pancreatic neuroendocrine tumor metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000769-19-FRovartis Pharma Services AG140
进行中（未招募）
不适用
Safety and efficacy of BEZ235 in patients with pancreatic neuroendocrine tumors (pNET)Adult patient in advanced pancreatic neuroendocrine tumorsMedDRA version: 14.1Level: LLTClassification code 10068916Term: Pancreatic neuroendocrine tumor metastaticSystem Organ Class: 100000004864EUCTR2012-000769-19-PLovartis Pharma Services AG140
已完成
2 期
Randomized phase II study of BEZ235 or everolimus in advanced pancreatic neuroendocrine tumorsNETpancreas neuroendocrine tumor10014713NL-OMON40098ovartis7
进行中（未招募）
1 期
Safety and efficacy of BEZ235 in patients with pancreatic neuroendocrine tumors (pNET)EUCTR2012-000769-19-GBovartis Pharma Services AG62
进行中（未招募）
不适用
Safety and efficacy of BEZ235 in patients with pancreatic neuroendocrinetumors (pNET)EUCTR2012-000769-19-ITOVARTIS FARMA140